Literature DB >> 3598236

Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans.

J J Treanor, R F Betts, S M Erb, F K Roth, R Dolin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3598236     DOI： 10.1093/infdis/156.2.379

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  11 in total

Review 1.  Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective.

Authors:  A E Pontiroli; A Calderara; G Pozza
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

2.  The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo.

Authors:  Kari Ann Shirey; Quan M Nhu; Kevin C Yim; Zachary J Roberts; John R Teijaro; Donna L Farber; Jorge C Blanco; Stefanie N Vogel
Journal:  J Leukoc Biol       Date:  2010-11-17       Impact factor: 4.962

3.  Biodegradable nanogels for oral delivery of interferon for norovirus infection.

Authors:  Yunjeong Kim; Mahendra Thapa; Duy H Hua; Kyeong-Ok Chang
Journal:  Antiviral Res       Date:  2010-12-07       Impact factor: 5.970

4.  Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults.

Authors:  J J Treanor; F K Roth; R F Betts
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

5.  Single-Cell Virus Sequencing of Influenza Infections That Trigger Innate Immunity.

Authors:  Alistair B Russell; Elizaveta Elshina; Jacob R Kowalsky; Aartjan J W Te Velthuis; Jesse D Bloom
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

Review 6.  Oromucosal Administration of Interferon to Humans.

Authors:  Manfred W Beilharz; Martin J Cummins; Alayne L Bennett; Joseph M Cummins
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-28

7.  Multi-scale modeling for the transmission of influenza and the evaluation of interventions toward it.

Authors:  Dongmin Guo; King C Li; Timothy R Peters; Beverly M Snively; Katherine A Poehling; Xiaobo Zhou
Journal:  Sci Rep       Date:  2015-03-11       Impact factor: 4.379

8.  Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year.

Authors:  Alayne L Bennett; David W Smith; Martin J Cummins; Peter A Jacoby; Joseph M Cummins; Manfred W Beilharz
Journal:  Influenza Other Respir Viruses       Date:  2013-02-09       Impact factor: 4.380

Review 9.  Interferons at age 50: past, current and future impact on biomedicine.

Authors:  Ernest C Borden; Ganes C Sen; Gilles Uze; Robert H Silverman; Richard M Ransohoff; Graham R Foster; George R Stark
Journal:  Nat Rev Drug Discov       Date:  2007-12       Impact factor: 84.694

10.  Antiviral potential of human IFN-α subtypes against influenza A H3N2 infection in human lung explants reveals subtype-specific activities.

Authors:  Aline da Rocha Matos; Katharina Wunderlich; Sebastian Schloer; Klaus Schughart; Robert Geffers; Martine Seders; Marlous de Witt; Anmari Christersson; Rainer Wiewrodt; Karsten Wiebe; Peter Barth; Andreas Hocke; Stefan Hippenstiel; Katja Hönzke; Ulf Dittmer; Kathrin Sutter; Ursula Rescher; Svetlana Rodionycheva; Nicoletta Matera; Stephan Ludwig; Linda Brunotte
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.